BRIM Biotechnology Inc

BRIM Biotechnology Inc has a strong liquidity position, with a current ratio of 53.17, indicating that its current assets significantly exceed its current liabilities. The company holds substantial cash and equivalents of TWD 839.61 million, which is a significant portion of its total assets of TWD 1.74 billion. The price-to-book ratio of 1.68 suggests that the market values the company at a premium to its book value, but the absence of long-term debt and a debt-to-equity ratio of 0.0 indicate a conservative capital structure.

Profitability metrics for BRIM Biotechnology Inc are negative, with a return on equity (ROE) of -2.23% and a return on assets (ROA) of -2.19%. These figures are below the typical performance benchmarks for the biotechnology industry, which often experiences early-stage losses before achieving profitability. The company reported a net loss of TWD 38.004 million and an operating loss of TWD 55.317 million in the latest period.

The company's revenue is currently reported at TWD 0.0, indicating that it is in the early stages of commercialization or has not yet generated revenue from its products. This aligns with the typical lifecycle of biotechnology firms, which often focus on research and development before achieving market entry. The absence of revenue concentration data suggests that the company is not yet generating revenue from specific segments or geographic regions.

Looking ahead, the company is expected to continue experiencing losses, with no immediate signs of revenue generation. The operating cash flow of TWD -48.432 million and free cash flow of TWD -37.571 million indicate that the company is not yet generating positive cash flows from operations. The capital expenditure of TWD -1.174 million suggests ongoing investment in infrastructure or research and development.

The risk assessment for BRIM Biotechnology Inc indicates low liquidity and dilution risks. The company has no immediate filing-based liquidity or dilution flags, and the absence of long-term debt and the presence of substantial cash reserves suggest a strong financial position. The low dilution risk is further supported by the fact that the number of shares outstanding has not changed between basic and diluted shares.

Recent events and filings do not indicate any significant changes in the company's financial or operational status. The company has not disclosed any major regulatory or legal issues, and there are no indications of near-term pressure for equity dilution. The company's financial position remains stable, with no immediate threats to its liquidity or capital structure.

Revenue surged 24,854.5% year-over-year to TWD 5.49 million, indicating significant commercial traction.

The company maintains a zero debt-to-equity ratio, ranking above the 75th percentile of its pharmaceutical cohort.

Cash conversion efficiency stands at 1.27, outperforming the pharmaceutical cohort median of 0.95.

The company faces high credit risk, signaling potential difficulties in securing favorable financing terms.

Return on invested capital is negative at -3.24%, indicating inefficient capital deployment.